Canakinumab for Pyoderma Gangrenosum
NCT01302795
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
5
Enrollment
OTHER
Sponsor class
Conditions
Pyoderma Gangrenosum
Interventions
DRUG:
Canakinumab
Sponsor
University of Zurich